Our customer service representatives are available 24 hours a day, from Monday to Sunday.

PDRN (Polydeoxyribonucleotide)

Online Inquiry

General Information

Product Name: PDRN (Polydeoxyribonucleotide)
Trade Name: Sodium DNA
Grade: Cosmetic Grade
Catalog: CI-PD-001
Applications: PDRN has the effects of repairing tissue, promoting wound healing and reducing inflammation, so it is widely used in mesotherapy, fillers and intra-articular injections.

Product Description

PDRN originates from reproductive cells of salmon or chum salmon where it contains both 50% double-stranded and 90% single-stranded deoxyribonucleotides and shows a 98% sequence similarity to human DNA bases.

Clinical evidence demonstrates that PDRN displays minimal immune response and toxicity alongside negligible human body side effects like rejection and allergic reactions. Medical research has proven that PDRN is a compound that promotes tissue repair, diminishes inflammation levels and activates cell regeneration mechanisms.

We produce our PDRN by extracting it from salmon sperm DNA and subjecting it to a controlled purification followed by sterilization procedures. Alfa Chemistry produces PDRN which serves multiple fields such as regenerative medicine, dermatology and aesthetics while maintaining strict quality standards to guarantee reliable performance in research and commercial applications.

High Purity
Wide Molecular Weight Range
Biocompatible Sourcing & Controlled Stability

Product Specifications

Items	Specification
Grade	Cosmetic Grade
Appearance	White powder
Molecular Weight	50 - 1,500 kDa (size-exclusion chromatography)
Source	Salmon sperm (or alternative sources upon request)
Recommended usage	0.5%-2%
Purity	99%
Test	HPLC/UV
Applications	Mesotherapy and dermal-fillers
Packaging	1g, 5g, 10g, 25g, 100g
Hot Tags	PDRN for cosmetics, for human nutritional, food supplements.

Action Mechanism of PDRN

PDRN exerts its therapeutic effects through multiple interconnected pathways, including:

Schematic diagram of how PDRN fights the skin aging process. Skin aging process and PDRN mechanism of action. [1]

Adenosine A_2A Receptor Activation

PDRN binds to adenosine A_2A receptors, modulating inflammatory responses, apoptosis, and tissue repair.
Activation inhibits ROS-triggered NF-κB and MAPK signaling pathways, suppressing pro-inflammatory cytokines (e.g., TNF-α, IL-12) and enhancing anti-inflammatory cytokines (e.g., IL-10).
Increased cAMP levels via A_2A activation further block MAPK pathways, reducing oxidative stress and promoting healing.

Collagen Synthesis

A_2A receptor stimulation downregulates Fli1, a transcriptional repressor of collagen genes, while upregulating connective tissue growth factor (CTGF).
This cascade enhances collagen production in fibroblasts, validated by dose-dependent increases in collagen synthesis. Neutralizing CTGF abolishes this effect, confirming its role.

Anti-Inflammatory Effects

PDRN suppresses pro-inflammatory mediators (COX-2, IL-1β, IL-6, TNF-α) and elevates anti-inflammatory IL-10 in macrophages and chondrocytes.
Reduces apoptosis by lowering the Bax/Bcl-2 ratio, observed in models of colitis, arthritis, and lung injury.

Angiogenesis Enhancement

PDRN boosts vascular endothelial growth factor (VEGF) expression via A_2A receptors, promoting blood vessel formation (CD31, angiopoietin markers).
Demonstrated efficacy in ischemic models (e.g., femoral artery occlusion, burn wounds), with effects blocked by A_2A antagonist DMPX.

Melanogenesis Inhibition

Downregulates MITF (melanogenesis regulator) and suppresses tyrosinase activity (key enzyme in melanin synthesis).
Reduces expression of melanogenic proteins (TRP-1, TRP-2), lowering melanin production in melanocytes.

Frequently Asked Questions

Q1: Is PDRN safe for human use?

A: Yes. PDRN demonstrates biocompatibility and non-immunogenic properties with extensive clinical testing confirming its safe use.

Q2: How does PDRN differ from generic DNA extracts?

A: Stringent purification processes remove proteins and contaminants from PDRN to secure both optimal bioactivity and regulatory compliance.

Q3: Is it possible to mix PDRN with additional active ingredients such as hyaluronic acid?

A: Absolutely. PDRN works well with many medical and cosmetic products by strengthening combined results.

Q4: What is the recommended dosage for topical products?

A: Typical concentrations range from 0.5% to 2% (w/v), depending on the application. Consult our technical team for protocol optimization.

Reference

Khan, Aawrish, et al. Chinese Journal of Plastic and Reconstructive Surgery, 2022, 4(4), 187-193.

Case Study

PDRN for Accelerated Healing Post-Fractional Laser Resurfacing in Rat Models

Effects of PDRN treatment on promoting wound healing in CO2 laser-induced rats. Yu, Mi, et al. Journal of CosmetiC and laser therapy 19.1 (2017): 43-48.

This preclinical study evaluated daily injections of polydeoxyribonucleotide (PDRN) for promoting wound repair after fractional ablative CO₂ laser injury in rats. In a randomized, controlled study (n = 12 rats; 6 PDRN-treated, 6 vehicle controls), PDRN-treated wounds healed faster by multiple clinical and histological measures, showed greater granulation tissue formation, and exhibited marked increases in angiogenesis markers (VEGF and PECAM-1/CD31) versus controls — supporting PDRN as a candidate adjunct to improve recovery following ablative laser procedures.

Key Results

Enhanced Recovery: The PDRN-treated group demonstrated a faster wound healing process. Clinical assessments showed significantly less erythema and higher epithelial confluence on day 2. Furthermore, decreased crusting and an improved overall wound appearance were observed on both days 2 and 5 compared to the control group.
Improved Granulation Tissue Formation: Histopathological examination revealed that the granulation tissue thickness score was significantly higher in the PDRN-treated group on days 5 and 8 post-treatment.
Stimulation of Angiogenesis: The pro-angiogenic mechanism of PDRN was confirmed by immunohistochemistry. A significant increase in VEGF-positive cells was present in the treatment group compared to control on day 8. A significant increase in PECAM-1/CD31 positive microvessels was also seen in the PDRN-treated group. VEGF production was also augmented in the treatment group with a statistically significant increase in VEGF measured on day 8.

PDRN-Based Topical Cocktail (PDRN + Vitamin C + Niacinamide): Reducing UV-B–Driven Pigmentation and Restoring Dermal Matrix

A schematic diagram illustrating the reduction of UV-B skin damage by a combination of PDRN, vitamin C, and niacinamide. Kim, Hyoung Moon, et al. Molecules 27.4 (2022): 1276.

This preclinical study evaluated a topical liquid formulation combining polydeoxyribonucleotide (PDRN) with antioxidant/brightening actives (vitamin C and niacinamide; "PVN"), delivered using a microneedling therapy system (MTS), in an ultraviolet B (UV-B)–exposed animal model.

Formulations Tested: PVN (liquid): a mixture of PDRN, vitamin C, and niacinamide prepared immediately prior to application and sterilized by 0.2 μm filtration. In the study formulation, a 1 mM PVN solution contained 0.18 mM PDRN, 0.25 mM vitamin C, and 0.55 mM niacinamide. The preparation was administered topically via microneedling (MTS) in a UV-B photoaging/pigmentation animal model. Comparator arms included topical PDRN alone and hydroquinone (HQ).

Key Results:

PVN delivered via microneedling increased NRF2 and HO-1 expression in UV-B–irradiated skin. NADPH oxidase activity decreased and SOD activity rose in PVN-treated samples—changes consistent with diminished oxidative stress.
PVN (as well as PDRN and HQ) lowered levels of p53 and MITF and reduced tyrosinase activity; these molecular shifts were accompanied by reductions in skin melanin content, indicating suppression of UV-induced melanogenesis.
Expression of NF-κB and MMP2/3/9 was reduced following PVN, PDRN, and HQ treatments. This downregulation suggests minimized inflammatory signaling and decreased proteolytic degradation of dermal matrix components.
COL1A1 expression and collagen fiber abundance (Masson's trichrome) increased in treated skin. Elastin content and proteins associated with elastic fiber structure (fibrillin-1/2 and fibulin-5) were also elevated after PVN, PDRN and HQ applications, consistent with improved dermal structural integrity and potential gains in elasticity.